Developing a Natural History Model for Duchenne Muscular Dystrophy

Author:

Broomfield Jonathan1ORCID,Hill Micki2,Chandler Fleur3,Crowther Michael4,Godfrey Josie5,Guglieri Michela6,Hastie Jon3,Larkindale Jane7,Mumby-Croft Juliet8,Reuben Emily9,Woodcock Fionn8,Abrams Keith10

Affiliation:

1. University of Leicester College of Life Sciences

2. GSK: GlaxoSmithKline Plc

3. Sanofi

4. Karolinska Institute: Karolinska Institutet

5. JG Zebra Consulting

6. Newcastle University

7. Critical Path Institute

8. Source Health Economics

9. Duchenne UK

10. University of Warwick

Abstract

Abstract Background The aim of this study was to build a natural history model (NHM) for Duchenne muscular dystrophy (DMD) to provide new insights into the disease and to inform economic evaluations of new therapies. The study was conducted as part of Project HERCULES, a multi-stakeholder collaboration to develop tools to support the health technology assessment of new treatments for DMD. Methods Health states were identified based on a review of NHMs and input from clinicians, patients, and caregivers, and defined using outcomes commonly collected in clinical trials and real-world practice. The primary data source informing the NHM was the Critical Path Institute Duchenne Regulatory Science Consortium (D-RSC) database. This was supplemented, where data were scarce or absent, with expert input obtained via an elicitation exercise, and a systematic literature review and meta-analysis of mortality data. Results The NHM includes ambulatory, transfer, and non-ambulatory phases. Health states capture progression in each phase including loss of ambulation, ability to weight bear, and upper body and respiratory function, respectively. Scoliosis and cardiomyopathy were not included in health state definitions as the reporting of data in D-RSC for these diagnoses was poor. The NHM estimates that patients spend approximately 9.5 years in ambulatory states, 1.5 years in the transfer state, and the remainder of their lives in non-ambulatory states, with a median predicted survival of 29.8 years (95% CI: 29.1, 30.8). Conclusion The model developed includes a detailed disease pathway for DMD, including the clinically, patient, caregiver, and economically important transfer state which has not been identified or included in previous NHMs. The NHM will aid the understanding of disease milestones and may be used to support economic evaluations for new treatments for DMD, help facilitate inclusion of a lifetime time horizon within economic models and identify areas for further research.

Publisher

Research Square Platform LLC

Reference30 articles.

1. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis;Crisafulli S;Orphanet J Rare Dis,2020

2. Survival of patients with Duchenne muscular dystrophy;San Martín PP;Revista Chil de pediatria,2018

3. Forty-Five Years of Duchenne Muscular Dystrophy in The Netherlands;Bergen JC;J Neuromuscul Dis,2014

4. Progressive left ventricular dysfunction and long-term outcomes in patients with Duchenne muscular dystrophy receiving cardiopulmonary therapies;Wang M;Open Heart,2018

5. Duchenne muscular dystrophy;Duan D;Nat Rev Dis Primers,2021

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3